Why Sanofi Stock Could Keep Rising: Bullish Drivers Ahead

01. Historical Context

Why the current setup can still support more upside

The bull case starts with a simple fact: EUR 74.04 on May 15, 2026 is well below the analyst average target and only marginally above the 52-week low of EUR 71.73. That matters because upside stories work best when the starting valuation is not already stretched.

The operating evidence is solid. Q1 2026 net sales were EUR 10.509 billion, up 13.6% at constant exchange rates, while business EPS was EUR 1.88, up 14.0% at CER. Dupixent contributed EUR 4.2 billion in Q1 2026, up 30.8%; launches added EUR 1.2 billion, up 49.6%; vaccines were EUR 1.3 billion, up 2.1%. When a stock delivers that profile and still trades around 11x forward earnings, investors have to take the upside case seriously.

The bullish argument is not that Sanofi is suddenly a hyper-growth company. It is that the market still values the business like a lower-quality, slower-growth pharma than the current launch and immunology data justify.

Bullish setup for Sanofi using current verified datapoints — Upside framework anchored to the latest share price, recent results, and current valuation data.

Sanofi framework across investor time horizons

Horizon	What matters now	Current datapoint	What would strengthen the thesis
1-3 months	Execution versus guidance	Q1 2026 net sales were EUR 10.509 billion, up 13.6% at constant exchange rates, while business EPS was EUR 1.88, up 14.0% at CER.	Management keeps 2026 guidance and brand-level momentum remains intact.
6-18 months	Valuation versus revisions	MarketScreener showed Sanofi on about 12.9x trailing 2025 earnings, 10.9x 2026 estimated earnings, and 10.1x 2027 estimated earnings. Consensus EPS on MarketScreener was EUR 6.852 for 2026 and EUR 7.372 for 2027, implying about 7.6% growth into 2027.	Consensus EPS moves higher while the multiple does not need to do all the work.
To 2030	Structural compounding	10-year price range EUR 44.62 to EUR 94.70; 10-year CAGR 4.1%.	The company sustains growth through launches, pipeline conversion, and disciplined capital allocation.

02. Key Forces

Five bullish forces that could extend the move

The first bullish driver is continued Dupixent strength. More than 1.4 million patients are already being treated globally, and new approvals in 2026 further widened the franchise.

The second driver is launch velocity. Sanofi's new-product sales growth of 49.6% in Q1 2026 is the clearest proof that the company is building future revenue streams rather than simply harvesting legacy assets.

The third driver is valuation asymmetry. About 10.9x 2026 EPS and 10.1x 2027 EPS is a low bar if management can keep EPS growth at or above the rate of sales growth.

The fourth driver is sector positioning. J.P. Morgan says public healthcare multiples are at 30-year lows relative to the S&P 500. If investors rotate back into healthcare, Sanofi has room to benefit.

The fifth driver is operational leverage. Q1 2026 business EPS rose 14.0% at CER, slightly ahead of the sales growth rate, which shows the model can still convert growth into profit.

Current factor scorecard for Sanofi

Factor	Current Assessment	Bias	Why it matters now
Dupixent expansion	Q1 sales EUR 4.2 billion; new 2026 approvals	Bullish	The franchise is still expanding rather than maturing.
Launch momentum	Launch sales EUR 1.2 billion, up 49.6%	Bullish	This is the best evidence that future growth is broadening.
Valuation	10.9x 2026 EPS and 10.1x 2027 EPS	Bullish	The multiple leaves room for upside.
Sector setup	Healthcare cheap relative to the S&P 500 per J.P. Morgan	Bullish	Relative valuation can help if policy fear eases.
FX	FX still a headwind for reported numbers	Neutral	Good operating momentum can be obscured by currency.

03. Countercase

What could interrupt the rally

The bull case fails if investors decide Dupixent is too large a share of the story. Concentration is the single biggest reason Sanofi does not yet trade like a premium-growth name.

It also fails if launch momentum slows materially. A cheap stock is not automatically a bargain if new products do not scale into durable franchises.

Finally, it fails if healthcare remains a revision laggard. FactSet's May 1 note is a reminder that sector-level skepticism is still real even when individual companies execute well.

Current threats to the bullish thesis

Risk	Latest datapoint	Current assessment	Bias
Concentration	Dupixent around 40% of Q1 group sales	High but manageable	Neutral to Bearish
Launch fade	Current launch growth very strong	Would hurt the upside case if it slows sharply	Bearish if it happens
Sector skepticism	FactSet still flags weak healthcare earnings breadth	Still present	Neutral
FX optics	Reported growth can lag CER growth	Known issue	Neutral

04. Institutional Lens

What professional research implies for the upside case

Named institutional inputs are constructive enough to support a bull case, but only with discipline. MarketScreener consensus still points to a much higher average target than the recent price.

J.P. Morgan's 2026 healthcare note matters because it frames the sector as historically cheap relative to the market. FactSet matters because it shows the sector still lacks broad earnings support, which means upside will go to the stocks actually executing.

That combination is why Sanofi's bull case is plausible: low valuation, strong product momentum, and room for relative sector sentiment to improve.

Named institutional inputs used in this article

Source	Latest update	What it says	Why it matters here
MarketScreener, May 7, 2026	MarketScreener listed 24 analysts on May 7, 2026 with an Outperform consensus, average target EUR 97.10, low target EUR 82.00, and high target EUR 112.00.	Analysts still see upside because the stock is screening at a low-teens trailing P/E and about 11x forward earnings.	That institutional setup matters because Sanofi does not need an aggressive multiple to outperform if launches keep delivering.
IMF, April 2026	Global growth 3.1% in 2026 and 3.2% in 2027.	The IMF said downside risks still dominate because of conflict, fragmentation, and disappointment over AI productivity.	A slower macro tape usually limits multiple expansion for defensive growth names as well as cyclical names.
FactSet, May 1, 2026	Health Care was one of only two S&P 500 sectors reporting a year-over-year earnings decline; the S&P 500 forward P/E was 20.9x.	FactSet's message is that broad equity valuations are not cheap even as healthcare revisions remain mixed.	That raises the bar for stock-specific execution and makes relative valuation important.
J.P. Morgan Asset Management, 2026	Public healthcare multiples sit at 30-year lows relative to the S&P 500 despite USD 318 billion of M&A across 2,500-plus transactions in 2025.	J.P. Morgan's sector view is that policy noise has compressed healthcare valuations relative to the market.	That helps explain why solid pharma execution can still re-rate if policy fears fade.

05. Scenarios

How to trade or own the bullish case with clear triggers

A bullish setup is not the same as a blind buy. The right way to act on the upside case is to define what evidence would justify paying closer to the sell-side target range.

For Sanofi, the most useful checkpoints are whether Q2 2026 still shows strong launch growth, whether FY 2026 guidance is maintained, and whether 2027 EPS estimates keep firming from the current EUR 7.372 base.

Bullish scenario map for Sanofi

Scenario	Probability	Target range	Trigger	When to review
Fast bull	30%	EUR 95 to EUR 105	Stock re-rates toward the consensus target as execution stays clean through FY 2026.	Review after Q2 2026 and FY 2026.
Measured bull	45%	EUR 83 to EUR 94	Upside comes from earnings delivery more than multiple expansion.	Review after each quarterly result.
Bull case invalidated	25%	Below EUR 74	Launch growth cools and the market stops paying for a rerating thesis.	Review if the stock revisits the 52-week low.